129 related articles for article (PubMed ID: 36427340)
1. An observational analysis of disease burden in patients with cold agglutinin disease: Results from a large US electronic health record database.
Pham HP; Wilson A; Adeyemi A; Miles G; Kuang K; Carita P; Joly F
J Manag Care Spec Pharm; 2022 Dec; 28(12):1419-1428. PubMed ID: 36427340
[No Abstract] [Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Healthcare resource utilization among commercially insured patients with cold agglutinin disease in the United States.
Su J; Bylsma LC; Jiang X; Morales Arias J; Jain N; Nordyke RJ
J Med Econ; 2020 Aug; 23(8):902-907. PubMed ID: 32362156
[No Abstract] [Full Text] [Related]
4. Complement-mediated hemolysis persists year round in patients with cold agglutinin disease.
Röth A; Fryzek J; Jiang X; Reichert H; Patel P; Su J; Morales Arias J; Broome CM
Transfusion; 2022 Jan; 62(1):51-59. PubMed ID: 34813663
[TBL] [Abstract][Full Text] [Related]
5. Increased delay from initial concern to diagnosis of autism spectrum disorder and associated health care resource utilization and cost among children aged younger than 6 years in the United States.
Vu M; Duhig AM; Tibrewal A; Campbell CM; Gaur A; Salomon C; Gupta A; Kruse M; Taraman S
J Manag Care Spec Pharm; 2023 Apr; 29(4):378-390. PubMed ID: 36989447
[No Abstract] [Full Text] [Related]
6. Prolonged oral corticosteroid treatment in patients with systemic lupus erythematosus: An evaluation of 12-month economic and clinical burden.
Huang SP; DerSarkissian M; Gu YM; Duh MS; Wang MJ; Benson J; Vu J; Averell C; Bell CF
J Manag Care Spec Pharm; 2023 Apr; 29(4):365-377. PubMed ID: 36989451
[No Abstract] [Full Text] [Related]
7. Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300 U/mL) vs an alternative first-generation basal insulin.
Wright EE; Malone DC; Trujillo JM; Gill J; Huse S; Li X; Zhou FL; Preblick R; Reid T
J Manag Care Spec Pharm; 2022 Jun; 28(6):592-603. PubMed ID: 35352995
[No Abstract] [Full Text] [Related]
8. Autoimmune hemolytic anemia in hospitalized patients: 450 patients and their red blood cell transfusions.
Chen C; Wang L; Han B; Qin L; Ying B
Medicine (Baltimore); 2020 Jan; 99(2):e18739. PubMed ID: 31914091
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial.
Jäger U; D'Sa S; Schörgenhofer C; Bartko J; Derhaschnig U; Sillaber C; Jilma-Stohlawetz P; Fillitz M; Schenk T; Patou G; Panicker S; Parry GC; Gilbert JC; Jilma B
Blood; 2019 Feb; 133(9):893-901. PubMed ID: 30559259
[TBL] [Abstract][Full Text] [Related]
10. Red Blood Cell Transfusion in Patients With Autoantibodies: Is It Effective and Safe Without Increasing Hemolysis Risk?
Park SH; Choe WH; Kwon SW
Ann Lab Med; 2015 Jul; 35(4):436-44. PubMed ID: 26131416
[TBL] [Abstract][Full Text] [Related]
11. Health care resource utilization and costs associated with treatment among patients initiating calcitonin gene-related peptide inhibitors vs other preventive migraine treatments in the United States.
Varnado OJ; Manjelievskaia J; Ye W; Perry A; Schuh K; Wenzel R
J Manag Care Spec Pharm; 2022 Aug; 28(8):818-829. PubMed ID: 35876297
[No Abstract] [Full Text] [Related]
12. Cold agglutinin disease burden: a longitudinal analysis of anemia, medications, transfusions, and health care utilization.
Mullins M; Jiang X; Bylsma LC; Fryzek JP; Reichert H; Chen EC; Kummar S; Rosenthal A
Blood Adv; 2017 May; 1(13):839-848. PubMed ID: 29296728
[TBL] [Abstract][Full Text] [Related]
13. Health care utilization and costs associated with functional status in patients with psoriatic arthritis.
Ogdie A; Hwang M; Veeranki P; Portelli A; Sison S; Shafrin J; Pedro S; Hass S; Hur P; Kim N; Yi E; Michaud K
J Manag Care Spec Pharm; 2022 Sep; 28(9):997-1007. PubMed ID: 36001101
[No Abstract] [Full Text] [Related]
14. Healthcare resource utilization among patients with cold agglutinin disease in Denmark.
Vágó EK; Nicholson G; Horváth-Puhó E; Hooda N; Fryzek JP; Su J
Curr Med Res Opin; 2021 Oct; 37(10):1829-1835. PubMed ID: 34308723
[TBL] [Abstract][Full Text] [Related]
15. US health care utilization and costs in adult patients with atopic dermatitis by disease severity.
Wang X; Boytsov NN; Gorritz M; Malatestinic WN; Goldblum OM; Wade RL
J Manag Care Spec Pharm; 2022 Jan; 28(1):69-77. PubMed ID: 34949118
[No Abstract] [Full Text] [Related]
16. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
17. Development and electronic health record validation of an algorithm for identifying patients with Duchenne muscular dystrophy in US administrative claims.
Schrader R; Posner N; Dorling P; Senerchia C; Chen Y; Beaverson K; Seare J; Garnier N; Walker V; Alvir J; Mahn M; Merla V; Zhang Y; Landis C; Buikema AR
J Manag Care Spec Pharm; 2023 Sep; 29(9):1033-1044. PubMed ID: 37610111
[No Abstract] [Full Text] [Related]
18. Burden of illness in progressive fibrosing interstitial lung disease.
Singer D; Bengtson LGS; Conoscenti CS; Anderson AJ; Brekke L; Shetty SS; Brown KK
J Manag Care Spec Pharm; 2022 Aug; 28(8):871-880. PubMed ID: 35876293
[No Abstract] [Full Text] [Related]
19. Incremental cost burden among patients with severe uncontrolled asthma in the United States.
Burnette A; Wang Y; Rane PB; Chung Y; Princic N; Park J; Llanos JP; Lindsley AW; Ambrose CS
J Manag Care Spec Pharm; 2023 Jul; 29(7):825-834. PubMed ID: 37404066
[No Abstract] [Full Text] [Related]
20. Evaluation of clinical characteristics, health care resource utilization, and cost outcomes of hemophilia A carriers and noncarriers in the United States: A real-world comparative analysis.
Xing S; Batt K; Kuharic M; Bullano M; Caicedo J; Chakladar S; Markan R; Farahbakhshian S
J Manag Care Spec Pharm; 2023 Jun; 29(6):626-634. PubMed ID: 37276033
[No Abstract] [Full Text] [Related]
[Next] [New Search]
